Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAB-001d
- Development stage
- Preclinical
- Lead developer
- Zhongshan Laibo Ruichen Biopharmaceutical
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
RAB-001d is a peptide-drug conjugate (PDC) bioconjugate currently under development by ZhongShan LaiBo RuiChen BioMedicine (also known as RabPharma). Designed for intravenous administration, the drug is specifically being investigated for the treatment of osteoarthritis (OA). As part of a specialized pipeline focusing on bone and joint health, RAB-001d likely utilizes a targeting peptide to deliver a therapeutic payload directly to affected joint tissues, aiming to improve efficacy and reduce systemic side effects compared to conventional therapies. It is currently in the preclinical or IND-enabling stage of development.
Beyond the preview
Go deeper on RAB-001d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAB-001d.